

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

-- SECRETARY OF THE S
06 FEB 16 AM 11:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name SCHERING-PLOUGH LEGISLATIVE RESOURCES L.L.C.			
2. Address <input type="checkbox"/> Check if different than previously reported 1130 Connecticut Ave., NW Suite 500 Washington DC 20036 USA			
3. Principal place of business (if different than line 2) City _____ State/Zip or Country _____			
4a. Contact Name Mrs. Marra Bussey	b. Telephone number 202-463-7372	c. E-mail marra.bussey@spcorp.com	5. Senate ID # 34502-12
7. Client Name <input checked="" type="checkbox"/> Self SCHERING-PLOUGH LEGISLATIVE RESOURCES L.L.C.			6. House ID # 33570000


TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>600,000</u></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of option.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Revenue Code</p>

[Edit Form >](#)

Signature  Date 2/14/06

Printed Name and Title Marra Bussey, Associate, Corporate Government Affairs

0000081005





Registrant Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

Client Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

ADDENDUM for General Lobbying Issue Area ANI

16. Specific lobbying issues (continued from previous page)

ing: H.R.1254, National Farm Animal Identification and Records Act; H.R. 3170, To establish a Livestock Identification Board to create and implement a mandatory national livestock identification.

Legislative proposals to affect US frequency standards for animal micro-chips: H.R.2744, Fiscal 2006 Agricul Appropriations.

1000081008

1

Registrant Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

Client Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

ADDENDUM for General Lobbying Issue Area HCR

16. Specific lobbying issues (continued from previous page)

H.R.1626, Medicare Prescription Drug Improvement Act; H.R.1669, Pharmacy Benefit Manager Transparency Act of 2005; H.R.2335, Meth-Endangered Children Protection Act of 2005; H.R.313, Exile Meth Act; H.R.314, Combat Meth Act of 2005; H.R.3199, Patient Act Reauthorization; H.R.328, Pharmaceutical Market Access Act of 2005; H.R.3324, Arrest Methamphetamine Act of 2005; H.R.3889, The Methamphetamine Elimination Act; H.R.3970, Bioterror Pandemic Preparedness Protection Act; H.R.4062, Pandemic Preparedness Response Act of 2005; H.R.417, Medical Innovation Prize Act of 2005; H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005; H.R.752, Medicare Prescription Drug Savings and Choice Act of 2005; H.R.798, Methamphetamine Remediation Act of 2005; H.R.870, Pharmaceutical research and Manufacturers Accountability Act of 2005, PhRMA Act of 2005; S.103, Combat Meth Act of 2005; S.109, Pharmaceutical Market Access Act of 2005; S.1128, Pharmaceutical Advertising and Prudent Purchasing Act of 2005; S.1361, A bill to amend the Controlled Substances Act to treat drug offenses involving crystal meth similarly to drug offenses involving crack cocaine; S.1437, Bioterror Pandemic Preparedness Protection Act; S.1821, Pandemic Preparedness Response Act; S.1873, Biodefense Pandemic Vaccine Drug Development Act of 2005; S.1880, National Biodefense Pandemic Preparedness Act of 2005; S.334, Pharmaceutical Market Access and Drug Safety Act of 2005; S.354, HEALTH Act of 2005, Health Efficient, Accessible, Low-Cost, timely Healthcare Act of 2005; S.764, Preserve Access to Affordable Drugs Act of 2005; S.873, Medicare Prescription drug Savings and Choice Act of 2005; S.930, Food and Drug Administration Safety Act of 2005.

Legislation controlling access to precursor chemicals for meth production and/or combating meth: H.R.1056, Methamphetamine Precursor Control Act of 2005; H.R.13, Clean, Learn, Educate, Abolish, Neutralize, and Undermine Production (CLEAN-UP) of Methamphetamine Act; H.R.1350, Methamphetamine Blister Pack Loophole Elimination Act of 2005; H.R.2335, Meth-Endangered Children Protection Act of 2005; H.R.313, Exile Meth Act; H.R.314, Combat Meth Act of 2005; H.R.3199, Patient Act Reauthorization; H.R.328, Pharmaceutical Market Access Act of 2005; H.R.3324, Arrest Methamphetamine Act of 2005; H.R.3889, The Methamphetamine Elimination Act; H.R.798, Methamphetamine Remediation Act of 2005; S.103, Combat Meth Act of 2005; S.109, A bill to amend the Controlled Substances Act to treat drug offenses involving crystal meth similarly to drug offenses involving crack cocaine.

Legislation regarding access to prescription drugs: H.CON.RES.75, Expressing the sense of the congress that the illegal importation of prescription drugs severely undermines the regulatory protections afforded to the United States consumers, and for other purposes; H.R.152, Preserving Access to Affordable Drugs Act of 2005; H.R.1572, Preserving Access to Affordable Drugs Act of 2005; H.R.1626, Medicare Prescription Drug Improvement Act; H.R.1669, Pharmacy Benefit Manager Transparency Act of 2005; H.R.328, Pharmaceutical Market Access Act of 2005; H.R.417, Medical Innovation Prize Act of 2005; H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005; H.R.752, Medicare Prescription Drug Savings and Choice Act of 2005; H.R.870, Pharmaceutical research and Manufacturers Accountability Act of 2005, PhRMA Act of 2005; S.109, Pharmaceutical Market Access Act of 2005; S.1128, Pharmaceutical Advertising and Prudent Purchasing Act of 2005; S.334, Pharmaceutical Market Access and Drug Safety Act of 2005; S.354, HEALTH Act of 2005, Health Efficient, Accessible, Low-Cost, timely Healthcare Act of 2005; S.764, Preserve Access to Affordable Drugs Act of 2005; S.873, Medicare Prescription drug Savings and Choice Act of 2005; S.930, Food and Drug Administration Safety Act of 2005.

Legislation regarding pandemic vaccine production: H.R.3970, Bioterror Pandemic Preparedness Protection Act; H.R.4062, Pandemic Preparedness Response Act; H.R.4603, Pandemic Seasonal Influenza Act of 2005; S.103, Bioterror Pandemic Preparedness Protection Act;

0101800000

Registrant Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

Client Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

ADDENDUM for General Lobbying Issue Area HCR

16. Specific lobbying issues (continued from previous page)

S.1821, Pandemic Preparedness Response Act; S.1873, Biodefense Pandemic Vaccine Drug Development / 2005; S.1880, National Biodefense Pandemic Preparedness Act of 2005.

0000081011

Add page to continue specific issues description for this iss

Registrant Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

Client Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

H.R.3971, Medicare Cost Sharing and Welfare Extension Act of 2005; H.R.4241, Deficit Reduction Act of 2005.

Legislative proposals to ban Medicare and Medicaid reimbursement for erectile dysfunction drugs: H. R.3971, Medicare Cost Sharing and Welfare Extension Act of 2005.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name		Covered Official Position (if applicable)
Larry	Atkins	
Paul	Ehrlich	
Robert	Lively	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

1000081012

Printed Name and Title Marra Bussey, Associate, Corporate Government Affairs

Registrant Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

Client Name SCHERING-PLOUGH LEGISLATIVE
RESOURCES L.L.C.

ADDENDUM for General Lobbying Issue Area MMM

16. Specific lobbying issues (continued from previous page)

Amendments and bill language related to changes in Medicare reimbursement to pharmacies for prescription drugs and changes to Medicaid best price rebate: H.R.4241, Deficit Reduction Act of 2005.

Add page to continue specific issues description for this iss

0000081013

